Shots: AstraZeneca to get $1.5B upfront ($1B in cash & 0.5B equity) plus $470M sales based milestones for Synagis. AZ has also sold US rights for its new candidate MEDI8897 to Sobi, for $175M milestone for BLA submission plus $110M development milestones & $60M non-contingent payment during 2019-2021 Sobi to get hold of the US […]Read More
